Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of <i>Candida auris</i> Infections

• Main Authors: Mahmoud Ghannoum (Author), Maiken Cavling Arendrup (Author), Vishnu P. Chaturvedi (Author), Shawn R. Lockhart (Author), Thomas S. McCormick (Author), Sudha Chaturvedi (Author), Elizabeth L. Berkow (Author), Deven Juneja (Author), Bansidhar Tarai (Author), Nkechi Azie (Author), David Angulo (Author), Thomas J. Walsh (Author)
• Format: Book
• Published: MDPI AG, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<i>Candida auris</i> is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to <i>C. auris</i> are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment....